About Institute of Genomic Medicine and Rare Disorders
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Institute of Genomic Medicine and Rare Disorders
During the past decade, Institute of Genomic Medicine and Rare Disorders conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on
average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)
2017-02-13
2019-03-07
Completed
215
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
2017-12-08
2023-06-01
Active, not recruiting
105
A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
2017-10-09
2020-02-10
Terminated
218
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Institute of Genomic Medicine and Rare Disorders
According to Clinical.Site data, the most researched conditions in "Institute of Genomic Medicine and Rare Disorders" are
"Adrenoleukodystrophy" (1 trials), "Primary Mitochondrial Disease" (1 trials) and "Primary Mitochondrial Myopathy" (1 trials). Many other conditions were trialed in "Institute of Genomic Medicine and Rare Disorders" in a lesser frequency.
Clinical Trials Intervention Types at Institute of Genomic Medicine and Rare Disorders
Most popular intervention types in "Institute of Genomic Medicine and Rare Disorders" are "Combination Product" (1 trials) and "Drug" (1 trials). Other intervention types were less common.
The name of intervention was led by "MIN-102" (1 trials), "Placebos" (1 trials), "elamipretide" (1 trials), "elamipretide open label treatment" (1 trials) and "placebo comparator" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Institute of Genomic Medicine and Rare Disorders
The vast majority of trials in "Institute of Genomic Medicine and Rare Disorders" are
2 trials for "All" genders and 1 trials for "Male" genders.
Clinical Trials Status at Institute of Genomic Medicine and Rare Disorders
Currently, there are NaN active trials in "Institute of Genomic Medicine and Rare Disorders".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in Institute of Genomic Medicine and Rare Disorders,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Institute of Genomic Medicine and Rare Disorders, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".